Jpmorgan Chase & CO Chemomab Therapeutics Ltd. Transaction History

Jpmorgan Chase & CO

$1.1 Trillion
Q1 2024

A detailed history of Jpmorgan Chase & CO transactions in Chemomab Therapeutics Ltd. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 1 shares of CMMB stock, worth $0. This represents 0.0% of its overall portfolio holdings.

Number of Shares

Holding current value

% of portfolio

0.0%

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$0.5 - $0.86 $0 - $0	1 New	1 $0
Q2 2022 Aug 11, 2022	SELL	$2.58 - $4.88 $1,942 - $3,674	-753 Closed	0 $0
Q1 2022 May 11, 2022	BUY	$3.53 - $7.2 $2,658 - $5,421	753 New	753 $4,000

Others Institutions Holding CMMB

# of Institutions

Shares Held

2.66M

Call Options Held

Put Options Held

Orbimed Advisors LLC San Diego, CA

2.24M
Shares

$2.17 Million
0.04% of portfolio
Ikarian Capital, LLC Dallas, TX

213K
Shares

$206,990
0.02% of portfolio
Two Sigma Investments, LP New York, NY

40K
Shares

$38,794
0.0% of portfolio
David A. Siegel Two Sigma Advisers, LP | New York, Ny

37.8K
Shares

$36,666
0.0% of portfolio
Kestra Private Wealth Services, LLC

31.2K
Shares

$30,303
0.0% of portfolio

View Full List

About Chemomab Therapeutics Ltd.

Ticker CMMB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 11,431,700
Market Cap $11.1M
Description
Chemomab Therapeutics Ltd., a clinical-stage biotech company, discovers and develops therapeutics for the treatment of inflammation and fibrosis. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (...

More about CMMB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account